红桂木凝集素受体在肺癌组织的表达及意义  

Expression of Artocarpus Lingnanensis Lectin Receptor in Human Lung Cancer

作　　者：刘康海[1] 熊灏[2] 廖烈君 尹利君[3] 朱其芳[3] 曾麒燕[3,4] 

机构地区：[1]广西玉林市第一人民医院,玉林537000 [2]广西卫生职业技术学院,南宁530021 [3]广西医科大学生物化学与分子生物学教研室,南宁530021 [4]广西高校生物分子医学研究重点实验室,南宁530021

出　　处：《基因组学与应用生物学》2015年第8期1647-1650,共4页Genomics and Applied Biology

基　　金：广西科技计划项目(桂科攻10124001A-23);广西自然科学基金(2011GXNSFA018195)共同资助

摘　　要：为探讨肺癌中红桂木凝集素(ALL)受体的表达及其临床意义,本研究应用凝集素亲和组化法检测45例原发性肺癌(鳞癌25例,腺癌20例),阴性对照采用20例癌旁正常肺组织。凝集素组化显示,28例(62.2%)肺癌和3例(15%)癌旁正常肺组织的红桂木凝集素受体表达阳性,差异具有显著性。红桂木凝集素受体表达与肺癌TNM分期、淋巴结转移、分化程度有关,但与年龄、性别、肿瘤大小、病理类型无关。To investigate the expression level of the receptor of Artocarpus lingnanensis lectin(ALL) and explore its clinical value in lung cancer, lectinhistochemistry was used to detect the receptor of ALL in 45 cases of lung cancer(25 cases of squamouscell carcinoma, 20 cases of adenocarcinoma). 22 pericancerous normal lung specimens were as the negative control group. The expression of ALL receptor was shown in 28(62.2%) lung cancer specimens and 3(15%) cases of normal lung specimens. There was a significant difference(p<0.01). The expression of ALL receptor was significantly associated with TNM stage, lymph node metastasis and differentiate degree, but not associated with age, gender, tumor size and pathological type.

关 键 词：红桂木凝集素 受体 肺癌 凝集素组化 

分 类 号：R734.2[医药卫生—肿瘤]